Form 4: Nuvalent Director Cameron Wheeler Reports Future Equity Grants Under 10b5-1 Plan

Nuvalent, Inc. Director Cameron Wheeler has filed a Form 4 detailing the future acquisition of restricted stock units and stock options effective June 18, 2025, under a pre-arranged Rule 10b5-1 plan.

Summary

• Cameron Wheeler, a Director of Nuvalent, Inc. and a partner at Deerfield Management Company, L.P., filed a Form 4 disclosing future equity grants.
• The filing indicates the acquisition of 2,647 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on June 18, 2025, at a price of $0.00 per share.
• Following this transaction, Mr. Wheeler will beneficially own 5,146 shares of Class A Common Stock directly.
• Additionally, Mr. Wheeler will acquire 4,147 stock options to purchase Class A Common Stock on June 18, 2025, with an exercise price of $75.53 per share.
• The RSUs and stock options are scheduled to vest in full on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, contingent on continued service.
• The stock options have an expiration date of June 18, 2035.
• The reporting person disclaims pecuniary interest in the reported securities, stating they are held for the benefit and at the direction of Deerfield Management Company, L.P.
• The transaction is noted as being made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of equity to a director is a standard practice that aligns interests and is generally viewed favorably as a retention and incentive mechanism. The use of a 10b5-1 plan adds transparency and compliance. There are no negative implications from this specific filing.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with long-term shareholder value through equity incentives.
• The use of a Rule 10b5-1 plan indicates a pre-arranged, transparent, and compliant approach to insider transactions.

Future Outlook

The document outlines future equity grants to a director, with vesting scheduled for June 18, 2026, or the date of the next annual meeting of stockholders, contingent on continued service. The stock options granted will expire on June 18, 2035.

Industry Context

This Form 4 filing is a routine disclosure of director compensation in the form of equity grants, common practice across various industries, including biotechnology, to align management and director incentives with shareholder interests. The use of a 10b5-1 plan is a standard compliance measure for pre-planned insider transactions.

Related Party Transactions

• Cameron Wheeler, the reporting person, is a partner in Deerfield Management Company, L.P., and disclaims pecuniary interest in the securities, stating they are held for the benefit and at the direction of Deerfield Management Company, L.P. This indicates a relationship where the director's beneficial ownership is tied to an investment firm.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's long-term performance, potentially benefiting shareholders if the company's stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The grants serve as an incentive and retention tool for the director, a key member of the company's governance.

Next Steps

• The RSUs and stock options are expected to vest on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Nuvalent Inc., NUVL, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Rule 10b5-1 Plan, Deerfield Management